Alkermes (ALKS) PT Lowered to $59 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Alkermes (ALKS) PT Lowered to $55 at Cowen
April 2, 2018 1:13 PM EDTCowen lowered its price target on Alkermes (NASDAQ: ALKS) to $55.00 (from $66.00) while maintaining an Outperform rating following the FDA'S RTF for the NDA for ALKS 5461.
"Amidst uncertainty over potential next steps which will play out over the coming months, out of... More
Alkermes (ALKS) PT Lowered to $45 at Cantor Fitzgerald
April 2, 2018 12:05 PM EDTCantor Fitzgerald lowered its price target on Alkermes (NASDAQ: ALKS) to $45.00 (from $50.00) while maintaining a Neutral rating.
... MoreIntra-Cellular Therapies (ITCI) Trades Lower in Sympathy with Peer Alkermes (ALKS)
April 2, 2018 7:48 AM EDTIntra-Cellular Therapies (NASDAQ: ITCI) shares were in focus Monday after peer Alkermes (NASDAQ: ALKS) received a refuse to file letter from the FDA for ALKS 5461 for the adjunctive treatment of major depressive disorder.
Alkermes declined 18% and Intra-Cellular Therapies traded lower by as much as 9%.
... MoreAlkermes plc (ALKS) Says it Received Refusal to File Letter From FDA for ALKS 5461
April 2, 2018 7:00 AM EDTAlkermes plc (Nasdaq: ALKS) today announced that it received a Refusal to File letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressant therapies.
Upon its preliminary review, the FDA has taken the position that it is unable to complete a... More
